Discovery through Partnership | Excellence through Quality
| Product Name | CCT196969 |
| Description |
RAF Inhibitor |
| Purity | 96% |
| CAS No. | 1163719-56-9 |
| Molecular Formula | C27H24FN7O3 |
| Molecular Weight | 513.53 |
| Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Properties
| Storage Temperature | -20ºC |
| Shipping Temperature | Blue Ice or 4ºC |
| Product Type | Inhibitor |
| Solubility | Soluble in DMSO |
| Source | Synthetic |
| Appearance | White Solid |
| SMILES | CC(C)C)C1=NN(C2=CC=CC=C2)C(NC(NC(C(F)=C3)=CC=C3OC4=C5C(NC(C=N5)=O)=NC=C4)=O)=C1 |
| Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection |
| Cite This Product | CCT196969 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-185) |
Biological Description
| Alternative Names | 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea, CCT-196969, CCT 196969 |
| Research Areas | Apoptosis, Cancer |
| Scientific Background | CCT196969 is a dual pan-RAF/SFK inhibitor with potent activity against BRAF and SRC kinases. While primarily developed for melanoma treatment, its inhibition of SRC kinase—a key player in neuronal signaling—suggests potential applications in neuroscience. SRC kinases are involved in synaptic plasticity and neuroinflammation, and their dysregulation is linked to neurodegenerative diseases. CCT196969’s ability to modulate these pathways may offer therapeutic insights into CNS disorders characterized by aberrant kinase activity. |
| References | 1. Girotti, M.R., et al. (2015) Cancer Cell 27.1: 85-96. |
Product Images
Chemical structure of CCT196969 (SIH-185), a RAF Inhibitor. CAS #: 1163719-56-9. Molecular Formula: C27H24FN7O3. Molecular Weight: 513.53 g/mol.
Powered by Bioz
Reviews
There are no reviews yet.